MIRAMOON PHARMA
Halting Degeneration
Our mission
At Miramoon, we develop neuroprotective therapies that slow the progression of the devastating symptoms experienced by patients with degenerative disorders, extending their therapeutic windows.
By halting the progression of rare and devastating diseases, we strive to give patients more time, better care, and renewed hope.
We are dedicated to preserving quality of life for as long as possible, so every patient and family can cherish the moments that matter most.
Our company
Miramoon Pharma, a spin-off of the University of the Basque Country and the Biogipuzkoa Health Research Institute, is revolutionizing the future of medicine.
Using a unique chemistry technology, we are developing a new generation of small molecules with promising results in ophthalmology, skeletal and cardiac muscle disorders, and central nervous system diseases.
At Miramoon Pharma, Science and Innovation drive our mission to transform the treatment of complex diseases. By slowing disease progression, we aim to increase patients’ chances of benefiting from new curative therapies. At Miramoon Pharma, science and innovation drive our mission to transform the treatment of complex diseases. By slowing disease progression, we aim to increase patients’ chances of benefiting from new curative therapies.
Our science
MP compounds promote cell survival by stabilizing intracellular calcium levels and protecting against oxidative stress–induced damage.
